''Edaravone Dexborneol Concentrated Solution'' on Inflammatory Biomarkers in Patients with Acute Ischemic Cerebral Infarction

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045950

Enrollment

Unknown

Registered

2021-04-30

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic cerebral infarction

Interventions

control group:Common therapy for acute cerebral infarction

experimental group:Common therapy with "Edaravone Dexborneol Concentrated Solution" for acute cerebral infarction

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.The patients had a newly-issued aortic atherosclerotic cerebral infarction within 48 hours; 2.Patients had a NIHSS score of 3 or greater; 3.Aged 18 to 85 years.

Exclusion criteria

Exclusion criteria: 1.The patient was diagnosed with severe diabetes; 2.The patient had been diagnosed with advanced cancer; 3.The patient was highly suspected of having autoimmune disease; 4.The patients was suffering from a severe infection.

Design outcomes

Primary

Measure	Time frame
Blood routine examination;Cytokines;Myeloperoxidase;cell free DNA;neutrophil extracellular traps;	—

Secondary

Measure	Time frame
D-Dimer;Glycosylated hemoglobin;	—

Countries

China

Contacts

Public ContactZhang xiangjian

The North Campus Hospital of the Second Hospital of Hebei Medical University

zhang6xj@aliyun.com+86 15803210578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026